Literature DB >> 8764013

Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein.

S Bertagnoli1, J Gelfi, G Le Gall, E Boilletot, J F Vautherot, D Rasschaert, S Laurent, F Petit, C Boucraut-Baralon, A Milon.   

Abstract

Two myxoma virus-rabbit hemorrhagic disease virus (RHDV) recombinant viruses were constructed with the SG33 strain of myxoma virus to protect rabbits against myxomatosis and rabbit viral hemorrhagic disease. These recombinant viruses expressed the RHDV capsid protein (VP60). The recombinant protein, which is 60 kDa in size, was antigenic, as revealed by its reaction in immunoprecipitation with antibodies raised against RHDV. Both recombinant viruses induced high levels of RHDV- and myxoma virus-specific antibodies in rabbits after immunization. Inoculations by the intradermal route protected animals against virulent RHDV and myxoma virus challenges.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8764013      PMCID： PMC190460     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  27 in total

1.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

2.  Mapping and sequencing of a gene from myxoma virus that is related to those encoding epidermal growth factor and transforming growth factor alpha.

Authors:  C Upton; J L Macen; G McFadden
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

3.  Oral vaccination of the fox against rabies using a live recombinant vaccinia virus.

Authors:  J Blancou; M P Kieny; R Lathe; J P Lecocq; P P Pastoret; J P Soulebot; P Desmettre
Journal:  Nature       Date:  1986 Jul 24-30       Impact factor: 49.962

Review 4.  Clinical and pathological features of viral haemorrhagic disease of rabbits and the European brown hare syndrome.

Authors:  P S Marcato; C Benazzi; G Vecchi; M Galeotti; L Della Salda; G Sarli; P Lucidi
Journal:  Rev Sci Tech       Date:  1991-06       Impact factor: 1.181

5.  Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

Authors:  D Panicali; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

6.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

Authors:  T J Wiktor; R I Macfarlan; K J Reagan; B Dietzschold; P J Curtis; W H Wunner; M P Kieny; R Lathe; J P Lecocq; M Mackett
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

Authors:  M P Kieny; R Lathe; R Drillien; D Spehner; S Skory; D Schmitt; T Wiktor; H Koprowski; J P Lecocq
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

8.  Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein.

Authors:  R Drillien; D Spehner; A Kirn; P Giraudon; R Buckland; F Wild; J P Lecocq
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Live recombinant vaccinia virus protects chimpanzees against hepatitis B.

Authors:  B Moss; G L Smith; J L Gerin; R H Purcell
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

10.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272
View more
  15 in total

1.  Symbiont survival and host-symbiont disequilibria under differential vertical transmission.

Authors:  M S Sánchez; J Arnold; M A Asmussen
Journal:  Genetics       Date:  2000-03       Impact factor: 4.562

2.  Strict Assembly Restriction of Peptides from Rabbit Hemorrhagic Disease Virus Presented by Rabbit Major Histocompatibility Complex Class I Molecule RLA-A1.

Authors:  Qingxu Zhang; Kefang Liu; Can Yue; Di Zhang; Dan Lu; Wenling Xiao; Peipei Liu; Yingze Zhao; Guolan Gao; Chunming Ding; Jianxin Lyu; William J Liu
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

3.  Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus.

Authors:  J Bárcena; M Morales; B Vázquez; J A Boga; F Parra; J Lucientes; A Pagès-Manté; J M Sánchez-Vizcaíno; R Blasco; J M Torres
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus.

Authors:  S Castañón; M S Marín; J M Martín-Alonso; J A Boga; R Casais; J M Humara; R J Ordás; F Parra
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins.

Authors:  Jean-Luc Guerin; Jacqueline Gelfi; Severine Boullier; Maxence Delverdier; Frederique-Anne Bellanger; Stephane Bertagnoli; Ingo Drexler; Gerd Sutter; Frederique Messud-Petit
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 6.  Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review.

Authors:  Joana Abrantes; Wessel van der Loo; Jacques Le Pendu; Pedro J Esteves
Journal:  Vet Res       Date:  2012-02-10       Impact factor: 3.683

Review 7.  The current status and future directions of myxoma virus, a master in immune evasion.

Authors:  Bart Spiesschaert; Grant McFadden; Katleen Hermans; Hans Nauwynck; Gerlinde R Van de Walle
Journal:  Vet Res       Date:  2011-06-09       Impact factor: 3.683

Review 8.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

9.  Conformational and thermal stability improvements for the large-scale production of yeast-derived rabbit hemorrhagic disease virus-like particles as multipurpose vaccine.

Authors:  Erlinda Fernández; Jorge R Toledo; Lídice Méndez; Nemecio González; Francisco Parra; José M Martín-Alonso; Miladys Limonta; Kosara Sánchez; Ania Cabrales; Mario P Estrada; Alina Rodríguez-Mallón; Omar Farnós
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

10.  In vitro permissivity of bovine cells for wild-type and vaccinal myxoma virus strains.

Authors:  Béatrice Pignolet; Jean-Luc Duteyrat; Aude Allemandou; Jacqueline Gelfi; Gilles Foucras; Stéphane Bertagnoli
Journal:  Virol J       Date:  2007-09-27       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.